ArticleJACC. Asia2026
Midterm Outcomes of a Novel Physician-Modified Inner-Branch Iliac Branch Device for Internal Iliac Artery Reconstruction.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anatomical eligibility of the Iliac Branch Device (IBD) remains limited, primarily caused by the additional common iliac artery (CIA) space occupied by its outer branch. Given that East Asian populations typically have smaller CIA diameters and lengths than Western populations, the anatomical eligibility of IBD in East Asians is <30%. Thus, we developed a novel Physician-Modified Inner Iliac Branch Device (PM-IIBD) to reduce CIA spatial demands. The PM-IIBD was used for 10 patients' internal iliac artery (IIA) reconstruction, achieving a 100% technical success with no perioperative complications. The 12-month postoperative CTA follow-up showed that no type I or III endoleaks and all EIA and IIA were patent. Seven cases showed sac shrinkage, and 3 showed sac stability. This study demonstrates the safety and efficacy of the PM-IIBD in CIA lesions. The PM-IIBD significantly reduces spatial demands on the CIA, expanding the anatomical eligibility for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.